UOC
PTCT icon

UBS O'Connor’s PTC Therapeutics PTCT Stock Holding History

UBS O'Connor’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,548
Closed -$711K – 413
2025
Q2 		$711K Sell
14,548
-8,805
-38% -$418K 0.02% 252
2025
Q1 		$1.19M Sell
23,353
-23,541
-50% -$1.17M 0.03% 170
2024
Q4 		$2.12M Buy
46,894
+15,459
+49% +$662K 0.05% 150
2024
Q3 		$1.17M Sell
31,435
-1,565
-5% -$52.4K 0.03% 260
2024
Q2 		$1.01M Buy
33,000
+18,000
+120% +$583K 0.03% 294
2024
Q1 		$436K Sell
15,000
-21,052
-58% -$590K 0.01% 341
2023
Q4 		$994K Sell
36,052
-6,549
-15% -$150K 0.03% 271
2023
Q3 		$955K Sell
42,601
-2,500
-6% -$93K 0.02% 338
2023
Q2 		$1.83M Sell
45,101
-9,662
-18% -$473K 0.04% 315
2023
Q1 		$2.65M Buy
54,763
+22,108
+68% +$1.01M 0.06% 227
2022
Q4 		$1.25M Buy
+32,655
New +$1.36M 0.02% 538
2022
Q2 		– Sell
-50,000
Closed -$1.87M – 995
2022
Q1 		$1.87M Buy
+50,000
New +$1.93M 0.02% 606
2015
Q4 		– Sell
-40,000
Closed -$1.07M – 525
2015
Q3 		$1.07M Buy
+40,000
New +$1.71M 0.01% 425

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's PTCT Position: Q3 2025 in Review

UBS O'Connor sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 14,548 shares — an estimated $711K sold.

UBS O'Connor first reported a position in PTCT in Q3 2015 and held it in 13 quarters. The position peaked at $2.65M in Q1 2023. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • UBS O'Connor reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 14,548 PTC Therapeutics shares in Q3 2025, an estimated $711K.
  • UBS O'Connor first reported a position in PTC Therapeutics in Q3 2015 and held it in 13 quarters.
  • UBS O'Connor's PTC Therapeutics position peaked at $2.65M in Q1 2023.
  • 294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.